- Home
- ACIU vs VCIC Comparison
ACIU vs VCIC Comparison
Compare ACIU & VCIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- VCIC
- Stock Information
- Founded
- ACIU 2003
- VCIC 2024
- Country
- ACIU Switzerland
- VCIC United States
- Employees
- ACIU N/A
- VCIC N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- VCIC
- Sector
- ACIU Health Care
- VCIC
- Exchange
- ACIU Nasdaq
- VCIC NYSE
- Market Cap
- ACIU 332.4M
- VCIC 293.0M
- IPO Year
- ACIU 2016
- VCIC 2024
- Fundamental
- Price
- ACIU $2.68
- VCIC $10.01
- Analyst Decision
- ACIU Strong Buy
- VCIC
- Analyst Count
- ACIU 2
- VCIC 0
- Target Price
- ACIU $12.00
- VCIC N/A
- AVG Volume (30 Days)
- ACIU 132.5K
- VCIC 6.1K
- Earning Date
- ACIU 11-05-2024
- VCIC 01-01-0001
- Dividend Yield
- ACIU N/A
- VCIC N/A
- EPS Growth
- ACIU N/A
- VCIC N/A
- EPS
- ACIU N/A
- VCIC N/A
- Revenue
- ACIU $48,505,404.00
- VCIC N/A
- Revenue This Year
- ACIU $85.33
- VCIC N/A
- Revenue Next Year
- ACIU $80.69
- VCIC N/A
- P/E Ratio
- ACIU N/A
- VCIC N/A
- Revenue Growth
- ACIU 4097200.00
- VCIC N/A
- 52 Week Low
- ACIU $2.25
- VCIC $9.96
- 52 Week High
- ACIU $5.14
- VCIC $10.20
- Technical
- Relative Strength Index (RSI)
- ACIU 27.49
- VCIC N/A
- Support Level
- ACIU $2.62
- VCIC N/A
- Resistance Level
- ACIU $3.02
- VCIC N/A
- Average True Range (ATR)
- ACIU 0.15
- VCIC 0.00
- MACD
- ACIU -0.05
- VCIC 0.00
- Stochastic Oscillator
- ACIU 9.52
- VCIC 0.00
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About VCIC VINE HILL CAP INVT CORP
Vine Hill Capital Investment Corp is a blank check company.